into how Cyp1b1 is functioning. Adropin has emerged as a strong candidate for mediation of Cyp1b1-deletion effects [66]. The conserved effects of Cyp1b1-deletion on hepatic gene expression are remarkably linked to extensive anti-diabetic effects (Table 4). These beneficial effects could be realized with Cyp1b1 inhibitors in vivo. Vascular and mammary effects of Cyp1b1 have been linked to estradiol hydroxylation, and are reversed with the selective inhibitor tetramethoxystilbene [12]. Selective inhibition may, therefore, have therapeutic potential, including with dietary flavonoids.
